The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: A randomized, double-blind pilot study

Journal of Cachexia, Sarcopenia and Muscle

Volumn 1, Issue 1, 2010, Pages 35-42

  Rozentryt, Piotr ^a   von Haehling, Stephan ^b   Lainscak, Mitja ^b,c   Nowak, Jolanta U ^a   Kalantar Zadeh, Kamyar ^d   Polonski, Lech ^a   Anker, Stefan D ^b,e  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c University Clinic of Pulmonary and Allergic Diseases Golnik   (Slovenia)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Body weight; Cachexia; Fat; Heart failure; Oral nutrition

Indexed keywords

ALPHA TOCOPHEROL; CALCIUM; CARBOHYDRATE; CAROTENOID; CHLORIDE; CHROMIUM; COPPER; CYANOCOBALAMIN; FLUORIDE; FOLIC ACID; IRON; LACTOSE; MAGNESIUM; MANGANESE; PANTOTHENIC ACID; PHOSPHORUS; PLACEBO; POTASSIUM; PYRIDOXINE; RETINOL; RIBOFLAVIN; SATURATED FATTY ACID; SELENIUM; SODIUM; THIAMINE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VITAMIN D; VITAMIN K GROUP; ZINC;

ADULT; ARTICLE; BODY COMPOSITION; BODY SIZE; BODY WEIGHT; CACHEXIA; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE MARKER; DOUBLE BLIND PROCEDURE; EXERCISE; FEASIBILITY STUDY; FEMALE; HEART FAILURE; HEART FUNCTION; HUMAN; MALE; NUTRITIONAL SUPPORT; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; WEIGHT GAIN;

EID: 78650650791     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-010-0008-0     Document Type: Article

References (33)

1. von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther. 2009; 121: 227-52.
2. Rauchhaus M, Koloczek V, Volk HD, Kemp M, Niebauer J, Francis DP, et al. Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol. 2000; 76: 125-33.
3. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart. 2004; 90: 464-70.
4. von Haehling S, Jankowska EA, Anker SD. Tumour necrosis factor-α and the failing heart: pathophysiology and therapeutic implications. Basic Res Cardiol. 2004; 99: 18-28.
5. Anker SD, Rauchhaus M. Insights into the pathogenesis of chronic heart failure: immune activation and cachexia. Curr Opin Cardiol. 1999; 14: 211-6.
6. Anker SD, Clark AL, Teixeira MM, Hellewell PG, Coats AJS. Loss of bone mineral in patients with cachexia due to chronic heart failure. Am J Cardiol. 1999; 83: 612-5.
7. Anker SD, Sharma R. The syndrome of cardiac cachexia. Int J Cardiol. 2002; 85: 51-66.
8. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997; 349: 1050-3.
9. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail. 2001; 3: 312-5.
10. Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet. 2003; 361: 1077-83.
11. Lainscak M, Keber I, Anker SD. Body composition changes in patients with systolic heart failure treated with beta blockers: a pilot study. Int J Cardiol. 2006; 106: 319-22.
12. Springer J, Filippatos G, Akashi YJ, Anker SD. Prognosis and therapy approaches of cardiac cachexia. Curr Opin Cardiol. 2006; 21: 229-33.
13. Kalantar-Zadeh K, Anker SD, Horwich TB, Fonarow GC. Nutritional and anti-inflammatory interventions in chronic heart failure. Am J Cardiol. 2008; 101(11A): 89E-103E.
14. Poehlman ET, Scheffers J, Gottlieb SS, Fisher ML, Vaitekevicius P. Increased resting metabolic rate in patients with congestive heart failure. Ann Intern Med. 1994; 121: 860-2.
15. Toth MJ, Gottlieb SS, Goran MI, et al. Daily energy expenditure in free-living heart failure patients. Am J Physiol. 1997; 272: E469-75.
16. von Haehling S, Doehner W, Anker SD. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res. 2007; 73: 298-309.
17. Volkert D, Berner YN, Berry E, Cederholm T, Coti Bertrand P, Milne A, et al. ESPEN Guidelines on Enteral Nutrition: geriatrics. Clin Nutr. 2006; 25: 330-60.
18. Cano N, Fiaccadori E, Tesinsky P, Toigo G, Druml W, DGEM (German Society for Nutritional Medicine), et al. ESPEN Guidelines on Enteral Nutrition: adult renal failure. Clin Nutr. 2006; 25: 295-310.
19. Anker SD, John M, Pedersen PU, Raguso C, Cicoira M, Dardai E, et al. ESPEN Guidelines on Enteral Nutrition: cardiology and pulmonology. Clin Nutr. 2006; 25: 311-8.
20. Kalantar-Zadeh K, Braglia A, Chow J, Kwon O, Kuwae N, Colman S, et al. An anti-inflammatory and antioxidant nutritional supplement for hypoalbuminemic hemodialysis patients: a pilot/feasibility study. J Ren Nutr. 2005; 15: 318-31.
21. Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006; 83: 735-43.
22. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol. 2004; 43: 1439-44.
23. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008; 27: 793-9.
24. Cicoira MA, Doehner W, Jankowska WA, Zanolla L, Zardini P, Ponikowski P, et al. Body composition and prognosis in 511 chronic heart failure patients: results from three European centers. Eur J Heart Fail Suppl. 2004; 3(Suppl): 69.
25. Hudgins LC, Parker TS, Levine DM, Gordon BR, Saal SD, Jiang XC, et al. A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers. J Lipid Res. 2003; 44: 1489-98.
26. Genton L, Kudsk KA. Interaction between enteric nervous system and the immune system: role of neuropeptides and nutrition. Am J Surg. 2003; 186: 253-8.
27. Rauchhaus M, Clark AL, Doehner W, Davos C, Bolger A, Sharma R, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol. 2003; 42: 1933-40.
28. Rauchhaus M, Coats AJS, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet. 2000; 356: 930-3.
29. Anker SD, Volterrani M, Egerer KR, Felton CV, Kox WJ, Poole-Wilson PA, et al. Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure. QJM. 1998; 91: 199-203.
30. Leyva F, Anker SD, Egerer K, Stevenson JC, Kox WJ, Coats AJS. Hyperleptinaemia in chronic heart failure. Relationships with insulin. Eur Heart J. 1998; 19: 1547-51.
31. Anker SD, Leyva F, Poole-Wilson PA, Kox WJ, Stevenson JC, Coats AJS. Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure. Heart. 1997; 78: 39-43.
32. Kovacic D, Marinsek M, Gobec L, Lainscak M, Podbregar M. Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. Clin Res Cardiol. 2008; 97: 24-31.
33. von Haehling S, Morley JE, Coats AJS, Anker SD (2010) Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle. doi: 10. 1007/s13539-010-0003-5.